-
Heim
-
Produkt
-
Immunhistochemie
-
INSTRUMENT
-
Molekular
-
HISTOLOGIE
-
ZYTOLOGIE
-
Digitale Pathologie
-
-
Solution
-
Unterstützung
-
Um
-
Kontakt
Produktkategorie
Kontaktieren Sie uns
ETV6/NTRK3 Fusion Gene t (12;15) Probe Reagent (Fluorescence in Situ Hybridization)
Clinic Signification：
1. Vitrakvi is the first FDA-approved oral TRK inhibitor to be marketed and also the first "broad-spectrum" anticancer drug that has nothing to do with tumor type. Targeted therapy for patients with NTRK gene (NTRK1/2/3) fusion , including: lung cancer, thyroid cancer, melanoma, gastrointestinal cancer, colon cancer, soft tissue sarcoma, salivary glands, infantile fibrosarcoma, appendix cancer, breast cancer, cholangiocarcinoma, pancreatic cancer etc.
Chat
Nachricht
Zitat
Contrast
ETV6/NTRK3
NTRK3/ETV6 Fusion
ETV6 Breakpart
Weitere Informationen
Probe Description: ETV6/NTRK3
Cat.No.: CF1078
Specification: 5 tests/box;10 tests/box, 20 tests/box
Verwandte Produkt
